Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (494)	11/9/2001 1:43:10 PM
From: tuck	Respond to of 1005

Double post, my bad, please continue.

To: tuck who wrote (494)	11/9/2001 1:43:20 PM
From: tuck	Read Replies (1) \| Respond to of 1005

Anyone care to comment on the possibility of further dilution at BDAL? A cursory glance at the balance sheet shows inventories up and cash down. They spend a lot on R&D, and if any of their launches disappoint they might not be able to finance from cash flow, which appears to be negative this q despite the small positive earnings. Waiting for the filing, which should be up next week, for a look at the statement of changes in financial position. Here's the other two statements, from the PR: Message 16609185 I'll be watching anecdotal evidence of order flow this quarter (i.e. read the PRs) looking for clues as to cash flow. But I currently think the odds are about even they'll do a financing soon. If that happens before it hits $16, I may move the cover and buy target down towards $13. I may not buy when I cover at $16, should it get there quickly, pending further analysis of the potential for dilution. BDAL putting meat on BLUE HP's table while it waits for that big turkey (VGNX) to finish roasting in Biotech Lock Up Expiration Hell. Cheers, Tuck